Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis.

Neuro-oncology - 3 May 2024

de Sauvage Magali A, Torrini Consuelo, Nieblas-Bedolla Edwin, Summers Elizabeth J, Sullivan Emily, Zhang Britney S, Batchelor Emily, Marion Braxton, Yamazawa Erika, Markson Samuel C, Wakimoto Hiroaki, Nayyar Naema, Brastianos Priscilla K

Abstract excerpt

BACKGROUND: Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment; however, only a subset of patients with brain metastasis (BM) respond to ICI. Activating mutations in the mitogen-activated protein kinase signaling pathway are frequent in BM. The objective of this study was to evaluate whether therapeutic inhibition of extracellular signal-regulated kinase (ERK) can improve the efficacy of ICI...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Extracellular Signal-Regulated MAP Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Melanoma

Share to Programmed Cell Death 1 Receptor

Share to Proto-Oncogene Proteins B-raf

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 38134951
DOI: 10.1093/neuonc/noad248
PMCID: PMC11066918

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis.PMID 38134951Read ↗

Microenvironmental correlates of immune checkpoint inhibitor response in human melanoma brain metastases revealed by T cell receptor and single-cell RNA sequencingSemantic proximity Read ↗

Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases.Semantic proximity Read ↗

Impact of Sequencing Radiation Therapy and Immune Checkpoint Inhibitors in the Treatment of Melanoma Brain MetastasesSemantic proximity Read ↗

Unraveling the Enigma of Melanoma Brain Metastasis: New Horizons in Mechanisms, Diagnosis, and TherapySemantic proximity Read ↗

Melanoma brain metastasis: overview of current management and emerging targeted therapies.Semantic proximity Read ↗

Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.Semantic proximity Read ↗

BRAF-MEK inhibition in melanoma brain metastases: a new hope.Semantic proximity Read ↗

Acquired and intrinsic resistance to vemurafenib in BRAF <sup>V600E</sup> -driven melanoma brain metastasesSemantic proximity Read ↗

Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.Semantic proximity Read ↗

Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity.Semantic proximity Read ↗

MET receptor activation by stromal cells serves as promising target in melanoma brain metastasesSemantic proximity Read ↗

Systemic therapies for melanoma brain metastases: which drug for whom and when?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.